1. "Unclassified" is not legal
This distinction is the foundation for everything else, and it is almost always misunderstood.
A banned substance appears on a list. An unclassified substance does not appear on any list—not because it has been evaluated and deemed safe, but because no one has examined it yet.
A seller who claims that their product “isn’t illegal” is therefore stating something that is literally true but completely meaningless. The absence of a classification is not authorization—it’s an administrative delay.
The distinction between what the plant produces and what comes out of a laboratory is detailed in our article on the three families of cannabinoids.
2. Regulatory Arbitrage
The economic mechanism is simple and perfectly rational from the perspective of those who exploit it.
Europe does not apply a single regulatory framework: each country maintains its own list, with its own deadlines for classification. It is therefore sufficient to establish operations where the classification process is slowest, then let the free movement of goods do the rest.
Several Central European countries have served as entry points in recent years, with Slovakia being one of the most well-documented cases during the previous wave. The country in question changes as legislation evolves; the mechanism itself remains the same.
A direct consequence for a buyer: a product legally ordered from a European supplier may contain a substance that is banned in your own country. Compliance is assessed at the destination, not at the time of shipment.
3. The Cycle, and Why It Cannot Stop
It always unfolds in the same order:
- A molecule circulates and attracts the attention of early-warning systems.
- After evaluation, it is added to a national list.
- A detail of its structure is modified —a group is moved, a chain is lengthened.
- The new version isn’t covered by any regulations. It’s put back on the market.
On the regulatory side, each iteration requires an assessment, a decision, and a publication: several months at best. On the production side, the modification and reintroduction into circulation take a few weeks.
It is therefore not a matter of political will or the severity of penalties. As long as classification proceeds molecule by molecule, the speed gap is structural.
4. Why the list-based approach has reached its limits
Two approaches coexist in Europe, and they do not yield the same results.
The nominative approach classifies each substance individually. It is legally precise and easy to challenge—but it is structurally outdated.
The generic approach defines an entire chemical family, prohibiting in advance all variants of the same structure. It closes the door to derivatives, but it is more difficult to draft and may capture molecules that are not of concern.
Several countries have begun to shift toward the second approach. It is the only one that changes the nature of the game —and it is also the one that exposes dealers to a sudden change in the status of inventory they had purchased in good faith.
5. What This Means for a Reseller
This is the part that directly affects you if you buy for resale.
The risk isn’t just buying a prohibited product. It’s buying a compliant product that will cease to be compliant before you’ve sold it.
Inventory purchased legally can become unsellable after a simple publication in the official gazette—in some cases, without a transition period. The loss is a total write-off, and it is not covered by your supplier.
Four checks are essential before placing any order:
- The complete composition, not just the listed concentration. An unfamiliar abbreviation should prompt a rejection, not a search.
- Analysis of the delivered batch, including its batch number as indicated on the merchandise.
- The supplier’s country of establishment and the actual length of the supply chain behind it.
- Compliance with the laws of your country of resale, not those of the seller.
The complete criteria for evaluating a supplier are in our guide on how to verify a supply chain, and the differences in thresholds between markets are covered in our article on what distinguishes Switzerland, France, and the European Union.
6. The Only Benchmark That Doesn’t Change
Trying to keep up with the list is a lost cause: it’s inherently outdated, and it changes faster than you can check it.
The reliable benchmark is the opposite—what the plant produces doesn’t change. CBD, CBG, CBN, CBC, terpenes: this list has been stable ever since botany established it, and it will remain so.
Hence a decision-making rule that fits into a single sentence and requires no legal monitoring: if the composition lists something you’d never seen six months ago, it’s not an innovation—it’s a workaround.
